

A MOTHERISK EDUCATIONAL PROGRAM

Reference List

Section 1 – General Principles of Teratology

The Management of Nausea and Vomiting of Pregnancy

1. Koren G. Maternal-fetal toxicology: A clinician's guide (Third Ed.); New York; Marcel Dekker Inc. 2001;37-71.
2. Brent RL. Addressing environmentally caused human birth defects. *Pediatr Rev* 2001;22(5):153-165.
3. Gadsby R et al. A prospective study of nausea and vomiting during pregnancy. *Br J Gen Pract* 1993;43:245-248.
4. Smith C et al. The impact of nausea and vomiting on women: a burden of early pregnancy. *Aust NZ J Obstet Gynaecol* 2000;40(4):397-401.
5. Lacroix R et al. Nausea and vomiting in pregnancy: a prospective study of its frequency, intensity, and patterns of change. *Am J Obstet Gynecol* 2000;182:931-937.
6. Mazzotta P et al. Therapeutic abortions due to severe morning sickness. *Motherisk Update. Can Fam Phys* 1997;43:1055-1057.
7. Mazzotta P, Magee LA. A risk-benefit assessment of pharmacological and non pharmacological treatments for nausea and vomiting of pregnancy. *Drugs* 2000;59(4):781-800.
8. Fischer-Rasmussen W et al. Ginger treatment of hyperemesis gravidarum. *Eur J Obstet Gynecol Reprod Biol* 1990;38:19-24.
9. Vutyavanich T et al. Ginger for nausea and vomiting in pregnancy: randomized, double-masked, placebo-controlled trial. *Obstet Gynecol* 2001;97:577-582.
10. Einarson A et al. Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling. *J Psychiatry Neurosci* 2001;26(1):44-48.
11. Koren G et al. Drugs in pregnancy. *N Engl J Med* 1998;338(16):1128-1137.
12. McKeigue P et al. Bendectin and birth defects: I. A meta-analysis of the epidemiologic studies. *Teratology* 1994;50:27-37
13. Einarson TR et al. A method for meta-analysis of epidemiological studies. *Drug Intell Clin Pharm* 1988;22(10):813-824.
14. Bishai R et al. Critical appraisal of drug therapy for nausea and vomiting of pregnancy: II. Efficacy and safety of Diclectin (doxylamine-B6). *Can J Clin Pharmacol* 2000;7(3):138-143.
15. Lee J et al. Longitudinal change in the treatment of nausea and vomiting of pregnancy in Ontario. *Can J Clin Pharmacol* 2000;7(4):205-208.
16. Neutel I. Variation in rates of hospitalization for excessive vomiting in pregnancy by Bendectin/Diclectin use in Canada. In: *Nausea and Vomiting of Pregnancy: State of the Art 2000*, Koren G and Bishai R, eds. *Motherisk*, Toronto 2000:54-59.
17. Neutel CI, Johansen HL. Measuring drug effectiveness by default: the case of Bendectin. *Can J Publ Health* 1995;86(1):66-69.
18. Lamm SH. The epidemiological assessment of the safety and efficacy of Bendectin. In: *Nausea and Vomiting of Pregnancy: State of the Art 2000*, Koren G and Bishai R, eds. *Motherisk*, Toronto. 2000:100-103.
19. Levichek Z et al., Nausea and Vomiting of Pregnancy: Evidence-based treatment algorithm. *Can Fam Phys* 2002;48:267-268,277.
20. Atanackovic G et al. The safety of higher than standard dose of doxylamine/pyridoxine (Diclectin®) for nausea and vomiting of pregnancy. *J Clin Pharmacol* 2001;41:842-845.
21. Seto A et al. Pregnancy outcome following first trimester exposure to antihistamines: meta-analysis. *Am J Perinat* 1997;14(3):119-124.

A MOTHERISK EDUCATIONAL PROGRAM

22. Sorensen HT et al. Birth outcome following maternal use of metoclopramide. *Br J Clin Pharmacol* 2000;49(3):264-268.
23. Berkovitch M et al. Fetal effects of metoclopramide therapy for nausea and vomiting of pregnancy. *N Engl J Med* 2000;343:445-446.
24. Sullivan CA et al. A pilot study of intravenous ondansetron for hyperemesis gravidarum. *Am J Obstet Gynecol* 1996;174(5):1565-1568.
25. Park-Wyllie L et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. *Teratology* 2000;62(6):385-392.
26. Frigo P et al. Hyperemesis gravidarum associated with helicobacter pylori seropositivity. *Obstet Gynecol* 1998;91:615-617.
27. Connolly A et al. Urinary tract infections in pregnancy. *Infections in Urology* 1999;26(4):779-780.
28. Millar LK, Cox SM. Urinary tract infections complicating pregnancy. *Infect Dis Clin North Am* 1997;11(1):13-26.
29. Delzell J et al. Urinary track infections during pregnancy. *Am Fam Physician, Kansas City* 2000.
30. Hernandez-Diaz S. Folic acid antagonists during pregnancy and the risk of birth defects. *N Engl J Med* 2000;343:1608-1614.
31. Hernandez-Diaz S et al. Neural tube defects in relation to use of folic acid antagonists during pregnancy. *Am J Epidemiol* 2001;153:961-968.
32. Ben David S et al. The safety of nitrofurantoin during the first trimester of pregnancy: a meta analysis. *Fundam Clin Pharmacol* 1995;9:503-507.
33. Reeves DS. Treatment of bacteriuria in pregnancy with single dose fosfomycin trometamol: a review. *Infection* 1992;20(4):S313-S316.
34. Loebstein R et al. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. *Antimicrob Agents Chemother* 1998;42:1336-1339.
35. Schaefer C et al. Pregnancy outcome after prenatal quinolone exposure: evaluation of a case registry of the European Network of Teratology Information Services. *Eur J Obstet Gynaecol* 1996;69:83-89.
36. Czeizel AE et al. A population-based case-control teratologic study of oral erythromycin treatment during pregnancy. *Reproductive Toxicol* 1999;13:531-536.
37. Loebstein R et al. Pregnancy outcome after gestational exposure to terfenadine: a multi-center, prospective study. *J Allergy Clin Immunol* 1999;104(5):953-956.
38. Schatz M, Zeiger RS. Asthma and allergy in pregnancy. *Clin Perinatol* 1997;24:407-432.
39. Mazzotta P et al. Treating allergic rhinitis in pregnancy. *Drug Saf* 1999;20:361-375.
40. Ellepola AN, Samaranyake LP. Inhalational and topical steroids, and oral candidosis: a mini review. *Oral Dis* 2001;7(4):211-216.
41. Werler MM et al. Maternal medication use and risks of gastroschisis and small intestinal atresia. *Am J Epidemiol* 2002;155(1):26-31.
42. National Asthma Education Program Report of the Working Group on Asthma and Pregnancy: management of asthma during pregnancy. NIH 1993;publication number 93-3279A.
43. Tan KS, Thomson NC. Asthma in pregnancy. *Am J Med* 2000;109(9):727-733.

A MOTHERISK EDUCATIONAL PROGRAM

44. Schatz M. Interrelationships between asthma and pregnancy: a literature review. *J Allergy Clin Immunol* 1999;103(2 Pt 2):S330-S336.
45. Schatz M et al. The safety of asthma and allergy medications during pregnancy. *J Allergy Clin Immunol* 1997;100(3):301-306.
46. Practice Guideline. The use of newer asthma and allergy medications during pregnancy. ACOG and ACAAI. *Ann Allergy Asthma Immunol* 2000;84:475-480.
47. Boulet LP et al. Canadian asthma consensus report, 1999. *CMAJ* 1999;161(11):S1-S5.
48. Rosenn B et al. Glycemic thresholds for spontaneous abortion and congenital malformations in insulin-dependent diabetes mellitus. *Obstetrics & Gynecology* 1994;84(4):515-520.
49. American Diabetes Association. Clinical practice recommendations: Gestational diabetes mellitus 2001:24(1).
50. Dixon D et al. Gestational diabetes mellitus: an update and review for primary care providers. *Physician Assistant*, March 1999.
51. Briggs G. et al, *Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk*, Sixth Ed. 2002;250-253.
52. Langer O et al. A comparison of glyburide and insulin in women with gestational diabetes mellitus. *N Engl J Med* 2000;343(16):1134-1138.
53. Hellmuth E et al, Oral hypoglycaemic agents in 118 diabetic pregnancies. *Diabetic Medicine* 2000;17:507-511.
54. Nulman I et al. Treatment of epilepsy in pregnancy. *Drugs* 1999;57(4):535-544.
55. Samren EB et al. Antiepileptic drug regimens and major congenital abnormalities in the offspring. *Ann Neurol* 1999;46(5):739-746.
56. Koch S et al. Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. *Acta Paediatr* 1996;84:739-746.
57. Paulson G. Headaches in women, including women who are pregnant. *Am J Obstet Gynecol* 1995;173:1734-1741.
58. Aube M. Migraine in pregnancy. *Neurology* 1999;53(1):S26-S28.
59. Welch K. Migraine and pregnancy. *Neurological Complications of Pregnancy*, ed: Devinsky O, Feldmann E, Hainline B, Raven Press, Ltd., New York, 1994.
60. Sumatriptan and Naratriptan Pregnancy Registry. Interim Report, 1 January 1996 through 31 October 2000. Glaxo Wellcome, January 2001.
61. Shuhaiber S et al. Pregnancy outcome following first trimester exposure to sumatriptan. *Neurology* 1998;51:581-583.
62. Product information. *Imitrex*. Glaxo Wellcome, 1998.
63. Kozer E et al. Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. *Am J Obstet Gynecol* 2002;187(6):1623-1630.
64. Nielsen GL et al. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population-based observational study and case-control study. *Br Med J* 2001;322:266-270.
65. Hickok DE et al. The association between decreased amniotic fluid volume and treatment with non-steroidal anti-inflammatory agents for preterm labour. *Am J Obstet Gynecol* 1989;160:1525-1531.
66. Koren G. et al. Maternal ginseng use associated with neonatal androgenization (Letter). *JAMA* 1990;264(22):2866.

A MOTHERISK EDUCATIONAL PROGRAM

67. ACOG Practice Bulletin: Use of botanicals for management of menopausal symptoms. *Clinical Management Guidelines for Obstetricians-Gynecologists* 2001;28:2.
68. Gallo M et al. The use of herbal medicine in pregnancy and lactation, in Koren G, ed., *Maternal and Fetal Toxicology*, 3rd ed., 2001:569-601.
69. Wilkinson JM. What do we know about herbal morning sickness treatments? A literature survey. *Midwifery* 2000;16:224-229.
70. Gibson PS et al. Herbal and alternative medicine use during pregnancy: a cross-sectional survey. *Obstet Gynecol* 2001;97(Suppl):44S.
71. Review of Natural Products, Facts and comparisons, May 2000.
72. Liu WHD. Ginger root, a new antiemetic. *Anaesthesia* 1990;45:1085.
73. Gallo M et al. Pregnancy outcome following gestational exposure to echinacea: a prospective controlled study. [Journal Article] *Arch Inter Med* 2000;160(20):3141-3143.
74. *Allium Sativum*. Garlic. PDR for Herbal Medicines, Montvale NJ: Medical Economics 1998:626-628.
75. Mennella JA et al. Garlic ingestion by pregnant women alters the odor of amniotic fluid. *Chem Senses* 1995;20:207-209.
76. Snell SB. Garlic on the baby's breath. *Lancet* 1973;2:43.
77. Ginkgo. The Review of Natural Products. St. Louis MO: Facts and comparisons. March, 1998. Ginkgo Biloba. PDR for Herbal Medicines., Montvale NJ: Medical Economics 1998:871-873.
78. Review of Natural Products. Facts and comparisons, February 2001.
79. Waller DP et al. Lack of androgenicity of Siberian ginseng. *JAMA* 1992;267:2329.
80. Chin R. Ginseng and common pregnancy disorders. *Asia-Oceania J Obstet Gynecol* 1991;17:379-380.
81. PDR for Herbal Medicines. Montvale NJ: Medical Economics 1998:905-908.
82. Haddad B, Sibai B. Chronic hypertension in pregnancy. *Ann Med* 1999;31:246.
83. The Magpie Trial Collaborative Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomized placebo-controlled trial.
84. Widerlov E et al. Hydralazine-induced neonatal thrombocytopenia. *N Engl J Med* 1980;303(21):1235.
85. Magee LA et al. The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. *Am J Obstet Gynecol* 1996;174(3):823-828.
86. Crooks BN et al. Adverse neonatal effects of maternal labetalol treatment. *Archives of Disease in Childhood: Fetal & Neonatal Edition* 1998;79(2):F150-F151.
87. Collins R et al. Overview of randomized trials of diuretics in pregnancy. *Br Med J* 1985;290:17-23.
88. Pryde PG et al. Angiotensin-converting enzyme inhibitor fetopathy. *J Am Soc Nephrol* 1993;3(9):1575-1582.
89. Hirschfeld RMA et al. The national depressive and manic-depressive association consensus statement on the undertreatment of depression. *JAMA* 1997.
90. Marcus S. Review Article: Treatment guidelines for depression in pregnancy. *Int J Gynecol Obstet* 2001;72:67.

A MOTHERISK EDUCATIONAL PROGRAM

91. Chambers CD et al. Birth outcomes in pregnant women taking fluoxetine. *N Engl J Med* 1996;335(14):1010-1015.
92. Nulman I et al. Neurodevelopment of children exposed in utero to antidepressant drugs. *N Engl J Med* 1997;336(4):258-262.
93. Nulman I et al. Child development following exposure to TCAs and fluoxetine throughout fetal life: a prospective controlled study. *Am J Psychiatry* 2002;159(11):1889-95.
94. Einarson A et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. *Am J Psychiatry* 2001;158(10):1728-1730.
95. Anonymous. American Academy of Pediatrics. Committee on Infectious Diseases. Varicella vaccine update. Practice Guideline. *Pediatrics* 2000;105(1 Pt 1):136-141.
96. McGregor JA, French JI. Bacterial vaginosis in pregnancy. *Obstet Gynecol Surv.* 2000;55(5 Suppl 1):S1-S19.
97. Caro-Paton T et al. Is metronidazole teratogenic? A meta-analysis. *Br J Clin Pharmacol* 1997;44(2):179-182.
98. Sobel JD. Use of antifungal drugs in pregnancy: a focus on safety. *Drug Saf* 2000;23(1):77-85.
99. Costei AM et al. Perinatal outcome following third trimester exposure to paroxetine. *Arch Pediatr Adolesc Med* 2002;156(11):1129-1132.
100. Gutzin S et al. The safety of oral hypoglycemic agents in the first trimester of pregnancy: a meta-analysis. *Can J Clin Pharmacol* 2003;10(4):179-83.
101. Helewa M. et al. Report of the Canadian Hypertension Society Consensus Conference: 1. Definitions, evaluation and classification of hypertensive disorders in pregnancy. *CMAJ* 1997;157(6):715-725.
102. Rey E. et al. Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy. *CMAJ* 1997;157(9):1245-1254.
103. Moore KL, Persaud TVN, *The developing human: clinically oriented embryology*, 7th edition, Saunders, 2003:520.
104. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. *Arch Pediatr Adolesc Med* 2004;158:312-6.
105. Koren G. Discontinuation syndrome following late pregnancy exposure to antidepressants. *Arch Pediatr Adolesc Med* 2004;158:307-8.

A MOTHERISK EDUCATIONAL PROGRAM

Section 2 – Micronutrient Supplementation in Pregnancy and Lactation

- MN-1 Vitamin & Mineral Deficiency. Investigating VM deficiency - a challenge to media professionals. 2004. 2004 World Economic Forum in Davos, Switzerland, UNICEF and the Micronutrient Initiative.
- MN-2 Hininger I. Favier M. Arnaud J. Faure H. Thoulon JM. Hariveau E. Favier A. Roussel AM. Effects of a combined micronutrient supplementation on maternal biological status and newborn anthropometrics measurements: a randomized double-blind, placebo-controlled trial in apparently healthy pregnant women. *Eur J Clin Nutr* 2004; 58: 52-9.
- MN-3 Health Canada . Nutrition for a Healthy Pregnancy: National Guidelines for the Childbearing Years. Ottawa. Minister of Public Works and Government Services Canada . 99. Minister of Health.
- MN-4 Dewey KG. Impact of breastfeeding on maternal nutritional status. *Adv Exp Med Biol* 2004; 554: 91-100.
- MN-5 Radhika MS. Bhaskaram P. Balakrishna N. Ramalakshmi BA. Devi S. Kumar BS. Effects of vitamin A deficiency during pregnancy on maternal and child health. *BJOG* 2002; 109: 689-93.
- MN-6 Dallaire F. Dewailly E. Shademani R. Laliberte C. Bruneau S. Rhainds M. Blanchet C. Lefebvre M. Ayotte P. Vitamin A concentration in umbilical cord blood of infants from three separate regions of the province of Quebec (Canada). *Can J Public Health* 2003; 94: 386-90.
- MN-7 Godel JC. Basu TK. Pabst HF. Hodges RS. Hodges PE. Ng ML. Perinatal vitamin A (retinol) status of northern Canadian mothers and their infants. *Biol Neonate* 1996; 69: 133-9.
- MN-8 Wein, E. E. Nutrient intakes of first nations people in four Yukon communities. *Nutr Res* 15(8), 1105-1119. 95.
- MN-9 Teratology Society position paper: recommendations for vitamin A use during pregnancy. *Teratology* 1987; 35: 269-75.
- MN-10 Van Allen, M. I., McCourt, C., and Lee, N. S. Preconception health: folic acid for the primary prevention of neural tube defects. A resource document for health professionals, 2002. 2002. Ottawa, Ontario: Minister of Public Works and Government Services Canada.
- MN-11 Health Canada. Why all women who could become pregnant should be taking Folic Acid. 2003. 2005.
- MN-12 Wilson RD. Davies G. Desilets V. Reid GJ. Summers A. Wyatt P. Young D. The use of folic acid for the prevention of neural tube defects and other congenital anomalies. *J Obstet Gynaecol Can* 2003; 25: 959-73. Notes: CORPORATE NAME: Genetics Committee and Executive and Council of the Society of Obstetricians and Gynaecologists of Canada.
- MN-13 National Institutes of Health. *Optimal calcium intake. NIH consensus statement* 1994; Jun 6-8; 12: 1-31.
- MN-14 Zhang C. Williams MA. Frederick IO. King IB. Sorensen TK. Kestin MM. Dashow EE. Luthy DA. Vitamin C and the risk of gestational diabetes mellitus: a case-control study. *J Reprod Med* 2004; 49: 257-66.
- MN-15 Zhang C. Williams MA. Sorensen TK. King IB. Kestin MM. Thompson ML. Leisenring WM. Dashow EE. Luthy DA. Maternal plasma ascorbic Acid (vitamin C) and risk of gestational diabetes mellitus. *Epidemiology* 2004; 15: 597-604.
- MN-16 Chappell LC. Seed PT. Briley AL. Kelly FJ. Lee R. Hunt BJ. Parmar K. Bewley SJ. Shennan AH. Steer PJ. Poston L. Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial. *Lancet* 1999; 354: 810-6.
- MN-17 Siega-Riz AM. Promislow JH. Savitz DA. Thorp JM Jr. McDonald T. Vitamin C intake and the risk of preterm delivery. *Am J Obstet Gynecol* 2003; 189: 519-25.
- MN-18 Lee BE. Hong YC. Lee KH. Kim YJ. Kim WK. Chang NS. Park EA. Park HS. Hann HJ. Influence of maternal serum levels of vitamins C and E during the second trimester on birth weight and length. *Eur J Clin Nutr* 2004.
- MN-19 Institute of Medicine, ed. *Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids*. Washington DC: National Academy Press, 2000.

A MOTHERISK EDUCATIONAL PROGRAM

- MN-20 Bohnsack BL. Hirschi KK. Nutrient regulation of cell cycle progression. *Annu Rev Nutr* 2004; 24: 433-53.
- MN-21 Bung P. Stein C. Prinz R. Pietrzik K. Schlebusch H. Bauer O. Krebs D. [Folic acid supply in pregnancy--results of a prospective longitudinal study]. *Geburtshilfe Frauenheilkd* 1993; 53: 92-9.
- MN-22 Wald NJ. Hackshaw AD. Stone R. Sourial NA. Blood folic acid and vitamin B12 in relation to neural tube defects. *Br J Obstet Gynaecol* 1996; 103: 319-24.
- MN-23 Hamaoui E. Hamaoui M. Nutritional assessment and support during pregnancy. *Gastroenterol Clin North Am* 2003; 32: 59-121, v.
- MN-24 Ravin CR. Fortifying oral contraceptives with folic acid. *AWHONN Lifelines* 2004; 8: 12-3.
Notes: CORPORATE NAME: Association of Women's Health, Obstetric and Neonatal Nurses.
- MN-25 Ray JG. Laskin CA. Folic acid and homocyst(e)ine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: A systematic review. *Placenta* 1999; 20: 519-29.
- MN-26 Scholl TO. Johnson WG. Folic acid: influence on the outcome of pregnancy. *Am J Clin Nutr* 2000; 71: 1295S-303S.
- MN-27 Smits LJ. Essed GG. Short interpregnancy intervals and unfavourable pregnancy outcome: role of folate depletion. *Lancet* 2001; 358: 2074-7.
- MN-28 Bruinse HW. van den Berg H. Changes of some vitamin levels during and after normal pregnancy. *Eur J Obstet Gynecol Reprod Biol* 1995; 61: 31-7.
- MN-29 Minister of Supplies and Services Canada, ed. *Nutrition recommendations. The report of the scientific review committee 1990. p116-123*. Ottawa: Minister of Supplies and Services Canada, 1990.
- MN-30 Ray JG. Folic acid food fortification in Canada. *Nutr Rev* 2004; 62: S35-9.
- MN-31 Hernandez-Diaz S. Werler MM. Walker AM. Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. *N Engl J Med* 2000; 343: 1608-14.
- MN-32 Alstead EM. Inflammatory bowel disease in pregnancy. *Postgrad Med J* 2002; 78: 23-6.
- MN-33 Wald NJ. Folic acid and the prevention of neural-tube defects. *N Engl J Med* 2004; 350: 101-3.
- MN-34 Oakley GP Jr. Bell KN. Weber MB. Recommendations for accelerating global action to prevent folic acid-preventable birth defects and other folate-deficiency diseases: Meeting of experts on preventing folic acid-preventable neural tube defects. *Birth Defects Res Part A Clin Mol Teratol* 2004.
- MN-35 Metz J. McNeil AR. Levin M. The relationship between serum cobalamin concentration and mean red cell volume at varying concentrations of serum folate. *Clin Lab Haematol* 2004; 26: 323-5.
- MN-36 Institute of Medicine, ed. *Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc*. Washington DC: National Academy Press, 2001.
- MN-37 Recommendations to prevent and control iron deficiency in the United States. Centers for Disease Control and Prevention. *MMWR Recomm Rep* 1998; 47: 1-29.
- MN-38 Turner RE. Langkamp-Henken B. Littell RC. Lukowski MJ. Suarez MF. Comparing nutrient intake from food to the estimated average requirements shows middle- to upper-income pregnant women lack iron and possibly magnesium. *J Am Diet Assoc* 2003; 103: 461-6.
- MN-39 Atallah AN. Hofmeyr GJ. Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. *Cochrane Database Syst Rev* 2002; CD001059.
- MN-40 Merialdi M. Carroli G. Villar J. Abalos E. Gulmezoglu AM. Kulier R. de Onis M. Nutritional interventions during pregnancy for the prevention or treatment of impaired fetal growth: an overview of randomized controlled trials. *J Nutr*

A MOTHERISK EDUCATIONAL PROGRAM

2003; 133: 1626S-1631S.

- MN-41 Delange F. [Iodine nutrition and neonatal hypothyroidism]. *Rev Med Brux* 1994; 15: 359-65.
- MN-42 Dunn JT. Iodine supplementation and the prevention of cretinism. *Ann N Y Acad Sci* 1993; 678: 158-68.
- MN-43 Hetzel BS. Mano MT. A review of experimental studies of iodine deficiency during fetal development. *J Nutr* 1989; 119: 145-51.
- MN-44 Choudhury N. Gorman KS. Subclinical prenatal iodine deficiency negatively affects infant development in Northern China. *J Nutr* 2003; 133: 3162-5.
- MN-45 Connolly KJ. Pharoah PO. Hetzel BS. Fetal iodine deficiency and motor performance during childhood. *Lancet* 1979; 2: 1149-51.
- MN-46 Hollowell JG. Staehling NW. Hannon WH. Flanders DW. Gunter EW. Maberly GF. Braverman LE. Pino S. Miller DT. Garbe PL. DeLozier DM. Jackson RJ. Iodine nutrition in the United States. Trends and public health implications: iodine excretion data from National Health and Nutrition Examination Surveys I and III (1971-1974 and 1988-1994). *J Clin Endocrinol Metab* 1998; 83: 3401-8.
- MN-47 International Council for the Control of Iodine Deficiency Disorders. Iodine Nutrition in Canada. 2004. 2004.
- MN-48 Merialdi M. Caulfield LE. Zavaleta N. Figueroa A. DiPietro JA. Adding zinc to prenatal iron and folate tablets improves fetal neurobehavioral development. *Am J Obstet Gynecol* 1999; 180: 483-90.
- MN-49 Merialdi, M., Caulfield, L. E., Zavaleta, N., Figueroa, A., Dominici, F., and DiPietro, J. A. Randomized controlled trial of prenatal zinc supplementation and the development of fetal heart rate. *Am J Obstet Gynecol* 190(4), 1106-12. 2004.
- MN-50 Merialdi M. Caulfield LE. Zavaleta N. Figueroa A. Costigan KA. Dominici F. DiPietro JA. Randomized controlled trial of prenatal zinc supplementation and fetal bone growth. *Am J Clin Nutr* 2004; 79: 826-30.
- MN-51 Dorea JG. Zinc deficiency in nursing infants. *J Am Coll Nutr* 2002; 21: 84-7.
- MN-52 Groenen PM. van Rooij IA. Peer PG. Ocke MC. Zielhuis GA. Steegers-Theunissen RP. Low maternal dietary intakes of iron, magnesium, and niacin are associated with spina bifida in the offspring. *J Nutr* 2004; 134: 1516-22.
- MN-53 Sukonpan K. Phupong V. Serum calcium and serum magnesium in normal and preeclamptic pregnancy. *Arch Gynecol Obstet* 2004.
- MN-54 Botto LD. Olney RS. Erickson JD. Vitamin supplements and the risk for congenital anomalies other than neural tube defects. *Am J Med Genet* 2004; 125C: 12-21.
- MN-55 French AE. Grant R. Weitzman S. Ray JG. Vermeulen MJ. Sung L. Greenberg M. Koren G. Folic acid food fortification is associated with a decline in neuroblastoma. *Clin Pharmacol Ther* 2003; 74: 288-94.
- MN-56 Olshan AF. Smith JC. Bondy ML. Neglia JP. Pollock BH. Maternal vitamin use and reduced risk of neuroblastoma. *Epidemiology* 2002; 13: 575-80.
- MN-57 Fronczak CM. Baron AE. Chase HP. Ross C. Brady HL. Hoffman M. Eisenbarth GS. Rewers M. Norris JM. In utero dietary exposures and risk of islet autoimmunity in children. *Diabetes Care* 2003; 26: 3237-42.
- MN-58 Hernandez-Diaz S. Werler MM. Louik C. Mitchell AA. Risk of gestational hypertension in relation to folic acid supplementation during pregnancy. *Am J Epidemiol* 2002; 156: 806-12.
- MN-59 Crowther CA. Hiller JE. Pridmore B. Bryce R. Duggan P. Hague WM. Robinson JS. Calcium supplementation in nulliparous women for the prevention of pregnancy-induced hypertension, preeclampsia and preterm birth: an Australian randomized trial. FRACOG and the ACT Study Group. *Aust N Z J Obstet Gynaecol* 1999; 39: 12-8.
- MN-60 Akyol D. Mungan T. Gorkemli H. Nuhoglu G. Maternal levels of vitamin E in normal and preeclamptic pregnancy. *Arch* 2006

A MOTHERISK EDUCATIONAL PROGRAM

Gynecol Obstet 2000; 263: 151-5.

- MN-61 Westphal LM. Polan ML. Trant AS. Mooney SB. A nutritional supplement for improving fertility in women: a pilot study. *J Reprod Med* 2004; 49: 289-93.
- MN-62 Bennett M. Vitamin B12 deficiency, infertility and recurrent fetal loss. *J Reprod Med* 2001; 46: 209-12.
- MN-63 Crha I. Hruby D. Ventruba P. Fiala J. Totusek J. Visnova H. Ascorbic acid and infertility treatment. *Cent Eur J Public Health* 2003; 11: 63-7.
- MN-64 Ahn E. Kapur B. Koren G. Iron bioavailability in prenatal multivitamin supplements with separated and combined iron and calcium. *J Obstet Gynaecol Can* 2004; 26: 809-14.
- MN-65 Steegers-Theunissen RP. Van Rossum JM. Steegers EA. Thomas CM. Eskes TK. Sub-50 oral contraceptives affect folate kinetics. *Gynecol Obstet Invest* 1993; 36: 230-3.
- MN-66 Ahn E. Nava-Ocampo AA. Koren G. Multivitamin supplements for pregnant women. New insights. *Can Fam Physician* 2004; 50: 705-6.
- MN-67 Chopra IJ. Baber K. Treatment of primary hypothyroidism during pregnancy: is there an increase in thyroxine dose requirement in pregnancy? *Metabolism* 2003; 52: 122-8.
- MN-68 Pletz MW. Petzold P. Allen A. Burkhardt O. Lode H. Effect of calcium carbonate on bioavailability of orally administered gemifloxacin. *Antimicrob Agents Chemother* 2003; 47: 2158-60.

TO RECEIVE A COPY OF ANY OF THE ABOVE STUDIES:

1-888-666-0611

info@drugs-in-pregnancy.org